1 / 27

CORPORATE PRESENTATION July - 2003

CORPORATE PRESENTATION July - 2003. Disclaimer.

alena
Download Presentation

CORPORATE PRESENTATION July - 2003

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. CORPORATEPRESENTATION July - 2003

  2. Disclaimer Except for the historical information   contained herein, statements  in this presentation and the subsequent discussions,which include words or phrases such as “will”, “aim”, “will likely result”, “would”, “believe”, “may”, “expect”,   “will continue”, “anticipate”,  “estimate”,   “intend”, “plan”, “contemplate”, “seek to”, “future”, “objective”, “goal”, “project”, “should”, “will pursue” and similar expressions or variations of such expressions may constitute  "forward-looking statements". These  forward-looking statements  involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking  statements. These risks and uncertainties include, but are not limited to our ability to successfully  implement our strategy, our  growth and expansion plans,  obtain regulatory approvals, our provisioning  policies, technological  changes, investment and  business income, cash  flow projections,  our exposure to market risks as well as other risks. Ranbaxy does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.

  3. Our Mission “To become a Research based International Pharmaceutical Company”

  4. Our Vision “To become a Billion Dollar Company by 2004”

  5. Corporate Highlights • Amongst the Top 100 Global Pharmaceutical Companies • 9th Largest Generic Company Worldwide* • Manufactures and Markets Generics, Branded Generics and APIs • Products available in over 70 countries with Ground presence in 25 countries and Manufacturing operations in 7 • 6 Core Markets - USA, India, UK, Germany, China and Brazil • Over 8000 multicultural, workforce * Amongst Publicly Traded Companies Source: MedAdNews – Nov’2002 Continued….

  6. Corporate Highlights • Global Net Sales US $ 764, a growth of 38% • 72 % Overseas Revenue • 28 Global Brands • NDDS : • 4 Platform Technologies • Cipro OD, once a day ciprofloxacin licensed to Bayer AG. Cipro XR 500mg was launched in US in Jan 2003 by Bayer AG. Approval from US FDA for 1gm awaited • NDDR : RBx 2258, First NCE licensed to Schwarz Pharma AG, undergoing Phase II Clinical Trials in India • 2 NDAs filed in 2002 (Metformin syrup, Ofloxacin OD tablets) NCE = New Chemical Entity , NDDS = Novel Drug Delivery Systems , NDDR = New Drug Discovery Research , NDA = New Drug Application

  7. Our International Presence • Core Markets • USA • India • UK • Germany • Brazil • China • Asia-Pacific & • Latin America • China • Vietnam • Malaysia • Thailand • Myanmar • Singapore • Brazil • Mexico • Peru • Venezuela • USA • India • Middle East • Sri Lanka • Saudi Arabia • Europe, CIS • & Africa • UK • Ireland • Poland • Russia • Germany • Ukraine • South Africa • Egypt • Nigeria • Kenya • Ivory Coast Products Available in over 70 Countries, Ground Presence in 25 Countries, 6 Core Markets

  8. Ranbaxy’s Strategic Architecture Horizon 3 Secure future options Value Horizon 2 Build momentum of emerging growth engines Innovative Research Horizon 1 Drive core growth Specialty Pharma International Generics • Global Generics Business • Critical Mass in Focus Markets - USA • Leveraging India Advantage • Brand Building in Developed Markets • Proprietary Technology Products • Networking and Alliances • Expanding Discovery Research • International Clinical Development • Rx Marketing Time

  9. Research & Development : Focus ANDAs NDDR NDDS RANBAXY 3 Key Areas NDDS = Novel Drug Delivery Systems , NDDR = New Drug Discovery Research, ANDA = Abbreviated New Drug Application

  10. R&D ... Key Priorities • A New Paradigm for ANDAs • Branded products through focussed NDDS applications • Drive Discovery Output and Enhance Early Discovery • Exploit Biotech Revolution for Innovative Pharmaceutical Research • Leverage Alliance Network • Increase Productivity and Shorten Development Timeline - New Processes, Automation and Efficient Organisational Structure • Develop Leaders at all Levels US $Million 50-60 CAGR ~ 50% 37 25 R&D Investments

  11. R&D ... Product Strategy GENERICS SPECIALITY PRODUCTS NCEs • ANDA filings • Para IVs • Blockbuster Para IIIs • Complex Technology and Niche Products • NDDS Products • NDAs , 505 b(2) • Pseudo Brands • Technology and Dosage Forms Innovations • Co-development and Collaborative Research • Derma, Paediatric, and Urology franchise • Long term play • Build expertise in Clinical Development • Research Alliances NCE = New Chemical Entity , NDDS = Novel Drug Delivery Systems , NDA = New Drug Application , ANDA = Abbreviated New Drug Application

  12. Drug Discovery Research NCE Pipeline RBx 2258 Urology- BPH Phase 2 Phase 1 RBx 7796 Pulmonary Bronchial Asthma RBx 7644 Anti-Bacterial Gram + Infection RBx 9001 Urology- BPH IND Filed RBx 9841 Urology- Overactive Bladder Pre-Clinical RBx 6198 Urology -BPH RBx 8700 Anti-Infective -Tuberculosis Late Discovery • New Therapeutic Areas • Metabolic Disorders, Anti-Inflammatory NCE – New Chemical Entity

  13. Novel Drug Delivery Systems Gastroretentive Cipro-OD and Oflox-OD 2 products launched Modified Matrix 8 products launched Products under development NDDS 4 Patented Platform Technologies Multi-particulate Products under development Aerogel Products under development • Value Added Drug Delivery Systems for • Taste Masking • Effervescent Tablets • Soft Gelatin Capsules • Topical Gels • Expansion into Transdermal and Inhalers

  14. International Regulatory Status Filings Approvals Filings 2002 Approvals Filings 2000 and 2001 Filings Approvals Approvals 1999 Western Europe China USA Brazil Excludes outsourced ANDAs

  15. Research & Development Center • Over 800 R&D Personnel • Dedicated Facilities for • Innovative Research • Generics Research • Drug Discovery Research • Therapeutic areas : Urology, Anti-Infectives, Pulmonary • Novel Drug Delivery Systems • Focus on Creating Rx products • Expand Technology Platforms • Conformance to International Regulatory Framework • Multiple Collaborative Research Programs • New Technologies / Areas • Biotechnology , Herbals • Expansion Plan to add 200,000 sq feet area R & D– I Gurgaon, India R & D - II Gurgaon, India

  16. Consolidated Financial Results - 2002 PBT / Sales ROCE Return on Capital Employed EBITDA = Earnings before Interest, Tax, Depreciation & Amortisation

  17. Global Sales

  18. Business Segment Contribution H1 - 2003 2002

  19. Focus on Pharmaceutical Sales 2002 Dosage Forms contribution at 85% 789** CAGR ~26 (Global Sales) 579 495 CAGR ~37 Dosage Forms **Gross Global Sales

  20. Manufacturing Strengths • Manufacturing Locations in Seven Countries • FDA-USA / MCA-UK / MCC-South Africa / TGA-Australia Approved Facilities • Established track record with FDA-USA • Successful Partnership with Vendors for Quality Compliance • High degree of Backward Integration • Cost Leadership • Producer of world class Generics, Branded Generics, Active Pharmaceutical Ingredients and Complex Molecules • Over 50 in-house APIs developed

  21. Manufacturing Presence USA China Ireland Malaysia Active Pharmaceuticals Ingredients (APIs)Facility, Mohali Dosage Forms Facility, Paonta Sahib] Nigeria Active Pharmaceuticals Ingredients (APIs) Facility, Toansa Dosage Forms Facility, Dewas Vietnam India

  22. India .. Strengths • Ranked 3 in Indian Retail Market with Domestic Market Share of 4.63% • Strong Brand Marketing Team with an extensive Distribution Network • 3 brands in top 25 • Strong Presence in Anti-Infectives, Cardiovascular, Anti-inflammatory & Dermatology segments • Growing Presence in Central Nervous System and Gastro Intestinal Tract, areas • 20 New Products Launched in the H1-2003 period (Chronic Therapy share 33.3% and Non Anti-infective 59.5%) • Largest Field Force comprising 1770 personnel Source: ORG MAT May 2003

  23. USA .. Leading International Expansion • Ranked No. 28 by prescription share • US sales for the H1-2003 were at US $213 Mn. • USA contributes 45% of the global sales (H1-2003) • It is the largest market for the Company • Strong ANDA pipeline • Para IVs ANDAs filed till date ~ 24 • Potential first to file for 8-9 out of 24 • Brand Market Initiative taken off with over 200 sales representatives. • Increasing Sales & Distribution reach CAGR 92%

  24. Other Core Markets • GERMANY • Sales of US $9 Mn.(2002) • Field Force of 43 for promotion to doctors • Focus on Inorganic acquisitions • UNITED KINGDOM • Sales of US $31 Mn. (2002) • Ranked 6th amongst Generics market share of 3.6% • 80 product lines • Brand Basket of 6-7 products • BRAZIL • Sales US $32 Mn. , growth ~100%(2002) • Largest international player in generics • Ranked 5th in generic segment and 53rd in overall • 19 new product launched in 2002 (17 generic, 2 branded) • ~ 100 products Approved / Under Received by ANVISA • CHINA • Secondary sales of ~ US $11.5 Mn. (2002) • Robust Pipeline for year 2003, including Cifran OD & Zanocin OD

  25. Way Forward • Building ‘Innovation’ Engine at R&D • Sustain growth momentum in USA • Attain critical mass in Europe and Latin America • Specialty products focus for “Brand” marketing • Fortifying home business – leverage India base • Seeding the Japanese market • Networking, licensing and acquisitions • Technology, new market entry vehicles, brands / proprietary products • Global talent pool to fuel growth

  26. Our Mission “To become a Research based International Pharmaceutical Company”

  27. Thank You

More Related